Ex Vivo Modeling of Acquired Drug Resistance in BRAF – Mutated Pancreatic Cancer Organoids Uncovers Individual Therapeutic Vulnerabilities

Researchers reported the ex vivo modeling of acquired drug resistance by creating a pancreatic ductal adenocarcinoma patient-derived tumor organoid model harboring a rare BRAF R506_K507ins VLR mutation resulting in a resistance to trametinib, a MEK inhibitor.